Several other equities research analysts have also recently weighed in on MOR. Commerzbank set a €76.00 ($93.83) target price on MorphoSys and gave the company a buy rating in a report on Tuesday, October 24th. Goldman Sachs Group set a €72.00 ($88.89) target price on MorphoSys and gave the company a neutral rating in a report on Wednesday, October 25th. Deutsche Bank set a €90.00 ($111.11) target price on MorphoSys and gave the company a buy rating in a report on Monday, October 30th. Berenberg Bank set a €85.00 ($104.94) target price on MorphoSys and gave the company a buy rating in a report on Wednesday, November 1st. Finally, JPMorgan Chase & Co. restated a buy rating and set a target price on shares of MorphoSys in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of €79.10 ($97.65).
Shares of MorphoSys (ETR MOR) opened at €75.05 ($92.65) on Tuesday. The firm has a market capitalization of $2,210.00 and a PE ratio of -25.44. MorphoSys has a fifty-two week low of €49.63 ($61.27) and a fifty-two week high of €87.35 ($107.84).
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.